Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (732)	6/23/2005 7:04:08 AM
From: Icebrg	Read Replies (1) \| Respond to of 1022

>>Anyone remember what happened with the LEXG / ABGX collaboration ?>> A good question. Not much it seems. Lexicon has cleaned out references to Abgenix from the Collaborations & Alliances part of their website. Abgenix on the other hand claims that: discover novel antibody drugs using targets derived from Lexicon's proprietary portfolio of full-length human genes. Under the alliance agreement, Lexicon and Abgenix each have the right to obtain exclusive commercialization rights, including sublicensing rights, for an equal number of qualifying antibodies. Each company will receive milestone payments and royalties on sales of antibody drugs from the collaboration that are commercialized by the other party or a third-party sublicensee. To date, scientists from both Lexicon and Abgenix have selected 13 human antigens from Lexicon's proprietary portfolio of novel, full-length human genes. Lexicon is utilizing its proprietary knockout technology to determine the biological function of these genes to help evaluate the medical relevance of the drug targets they encode. Simultaneously, Abgenix is applying its XenoMouse® technology to develop fully human antibodies directed at each of these drug targets. No doubt it was a set-back for Abgenix to lose Lexicon as a partner. But who knows what caused Lexicon's move. Was it because they feel Xoma can give them better antibodies or because they wanted to tap into XOMA's development expertise? Erik